Tivozanib Hydrochloride Patent Expiration

Tivozanib Hydrochloride is Used for treating advanced renal cell carcinoma by inhibiting angiogenesis with a vascular endothelial growth factor inhibitor in adults with certain treatment histories. It was first introduced by Aveo Pharmaceuticals Inc in its drug Fotivda on Mar 10, 2021.

Tivozanib Hydrochloride Patents

Given below is the list of patents protecting Tivozanib Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Fotivda US11504365 Use of tivozanib to treat subjects with refractory cancer Nov 05, 2039 Aveo Pharms
Fotivda US6821987 Quinoline derivatives and quinazoline derivatives having azolyl group Apr 26, 2025 Aveo Pharms
Fotivda US7166722 N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n′-(5-methyl-3-isoxazolyl)urea salt in crystalline form Nov 16, 2024 Aveo Pharms

Coming Soon

Patent Strength Analyzer

Will this be useful for you?


Thank you for your response 🥳